To all AlderBiopharmaceuticals visitors:

Alder Biopharmaceuticals is now a Lundbeck Company. For information about Alder and its pipeline, visit:

https://www.alderbio.com/pipeline/

For more information about Lundbeck and their acquisition of Alder, visit:

https://www.lundbeck.com/global/about-us/alder-biopharmaceuticals

A three-dimensional rendering of a monoclonal antibody (mAb).
EPTINEZUMAB

Our pivotal-stage monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP), and is currently in late-stage clinical development for the prevention of migraine.

LEARN MORE

A tablet on a stack of newspapers displaying the Alder BioPharmaceuticals website.
LATEST NEWS

Fundamental Change Company Notice

ALDER BIOPHARMACEUTICALS, INC. FUNDAMENTAL CHANGE COMPANY NOTICE AND OFFER TO REPURCHASE TO THE HOLDERS OF ALDER BIOPHARMACEUTICALS, INC. 2.50% Convertible Senior Notes due... LEARN MORE

The U.S. Food and Drug Administration (FDA) accepted Alder’s Biologics License Application for eptinezumab in April 2019, with a Prescription Drug User Fee Act (PDUFA) target action date of February 21, 2020.

CONTACT US General inquiries:
Click here

ADDRESS & PHONE / FAX Corporate Headquarters
Alder BioPharmaceuticals, Inc.
11804 North Creek Parkway South
Bothell, WA 98011

Phone: 425-205-2900
Fax: 425-205-2901